Контакты

411224, Россия г. Москва
ул. Набережная 123

Мы доступны 24/7. Звоните!
review:  

Neurotechnology is attracting some of the world's wealthiest people, including  Elon Musk, co-founder of Neuralink. Bill Gates and Jeff Bezos, other billionaires, have responded by investing in rival company Synchron. The competition for dominance in the field of neurotechnology is in full swing. While  Elon Musk recently successfully tested his Neuralink implant on a paralyzed man, others with vast fortunes have invested millions in Synchron, a startup company that, like Neuralink, seeks to transplant an implant into a person's brain, but through a less invasive procedure. Its investors include Bill Gates and Jeff Bezos.

Neuralink has helped usher in the era of the brain-computer interface

Synchron, a New York-based startup founded and led by psychology and neuroscience doctor Tom Oxley in 2016, has managed to raise 140 dollar million, making it a technological competitor to Neuralink and  Elon Musk. It even received funding from DARPA, a US federal agency specializing in military research.

Neuralink is using brain-computer interface (BCI) technology to develop Telepathy, a device designed to "directly connect the human brain to a computer". The chips are designed to give people with disabilities back the freedom of movement they have lost through the power of thought.

If  Elon Musk is to be believed, Neuralink will go far beyond this single mission in the future. The owner of Tesla and SpaceX is convinced that his chip will allow certain people to communicate telepathically, the blind to regain their sight, and even combine the human mind with artificial intelligence. Synchron, for its part, takes a different approach. Synchron's Stentrode microchip is inserted through a blood vessel into the patient's brain using a catheter, where it begins to pick up brain waves.

Introducing an innovation in neurotechnology

Dr. Tom Oxley's company wants to show that Neuralink isn't the only one shining in the field of neurotechnology. While  Elon Musk's device requires patients to undergo a complex surgery to implant the chip, which also needs to be done in a special clinic, Synchron has eschewed the procedure.

The startup wants to use stents to implant its brain chips. This method, which is much less invasive, has so far been used mainly in cardiology and vascular surgery. A stent can be compared to a small metal spring with a diameter of only a few millimeters. Some are even made of polylactic acid, a biodegradable polymer.

The appeal of Synchron

Synchron's appeal is obvious, so much so that it convinced famed Microsoft co-founder Bill Gates and Amazon creator Jeff Bezos to invest in the company. However, Synchron's proven technology is not without its challenges. The use of stents can lead to increased "noise" when reading brain signals, which can limit their accuracy. Whether it's Neuralink or Synchron, these advances could one day change the way we interact with technology and open up new opportunities for people with disabilities.

The battle for supremacy in mastering new technologies is only gaining momentum every year. Campaigns and geniuses are sparring as if in a sparring match, striving to surpass all competitors as we see in the example of Tom Oxley. And in fact, it is in competition that innovations are born, which are subsequently picked up by thousands of people, hundreds of campaigns and so on. All we have to do is watch for new trials of implants and chips. After all, one day this technology will definitely seep out of laboratories and test rooms and into our lives. We can only speculate how events in the field of neurotechnology will develop and how it will affect society in the future.

Similar news

Comments (0)

reload, if the code cannot be seen